Literature DB >> 10721921

Interactions mediating bacterial translocation in the immature intestine.

L C Duffy1.   

Abstract

Systemic disease caused by transmucosal passage of enterovirulent bacteria and toxins from the gut lumen into the mesenteric lymph nodes (MLN) is reviewed, with particular concern for bacterial interactions in the developing gut of premature newborns. Anaerobic bacteria are rarely observed to translocate to the MLN. Bifidobacterial strains have been tested for their abilities to adhere to enterocyte-like Caco-2 cells in culture. We have investigated the inhibitory effect of adherent human bifidobacterial strains against colonization by a number of diarrheagenic bacteria (Escherichia coli O157; Salmonella typhimurium) and viruses (murine and rhesus rotavirus), in various in vitro and in vivo models. The phagocytic cell (macrophage) may be a key factor in bacterial translocation (BT). Human breast milk contains abundant bioactive substances (immunologic, nutritional) that provide protective effects through inhibition of bacterial overgrowth and BT. New biotherapeutic therapies that stimulate beneficial anaerobic microflora (Lactobacillus, Bifidobacterium) are promising avenues of research to combat BT in disease treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10721921     DOI: 10.1093/jn/130.2.432S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  25 in total

1.  In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice.

Authors:  Elizabeth A Griffiths; Linda C Duffy; Floyd L Schanbacher; Haiping Qiao; Diane Dryja; Allen Leavens; Jon Rossman; Gary Rich; Douglas Dirienzo; Pearay L Ogra
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

2.  Effect of probiotic supplementation on bacterial translocation in common bile duct obstruction.

Authors:  Fatma Sarac; Tansu Salman; Feryal Gun; Alaaddin Celik; Nezahat Gurler; Semra Dogru Abbasoglu; Vakur Olgac; Ayse Saygili
Journal:  Pediatr Surg Int       Date:  2014-12-13       Impact factor: 1.827

3.  The effect of enteral supplementation of specific neutral and acidic oligosaccharides on the faecal microbiota and intestinal microenvironment in preterm infants.

Authors:  E A M Westerbeek; R A Slump; H N Lafeber; J Knol; G Georgi; W P F Fetter; R M van Elburg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-09       Impact factor: 3.267

4.  A three-dimensional mathematical and computational model of necrotizing enterocolitis.

Authors:  Jared Barber; Mark Tronzo; C Harold Horvat; Gilles Clermont; Jeffrey Upperman; Yoram Vodovotz; Ivan Yotov
Journal:  J Theor Biol       Date:  2012-12-07       Impact factor: 2.691

5.  Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity.

Authors:  Monique A S H Mennink-Kersten; Dorien Ruegebrink; Rocus R Klont; Adilia Warris; Françoise Gavini; Huub J M Op den Camp; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 6.  New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention.

Authors:  Michael P Sherman
Journal:  Clin Perinatol       Date:  2010-09       Impact factor: 3.430

7.  Effect of probiotic supplementation on bacterial translocation in thermal injury.

Authors:  Feryal Gun; Tansu Salman; Nezahat Gurler; Vakur Olgac
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 8.  Manipulation of the intestinal microbiome in newborn infants.

Authors:  Nicole Cacho; Josef Neu
Journal:  Adv Nutr       Date:  2014-01-01       Impact factor: 8.701

Review 9.  Neonatal sepsis: the gut connection.

Authors:  S Basu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-12       Impact factor: 3.267

Review 10.  The Developing Microbiome of the Preterm Infant.

Authors:  Mara E DiBartolomeo; Erika C Claud
Journal:  Clin Ther       Date:  2016-03-02       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.